Cognios Capital’s GSK GSK Stock Holding History

Cognios Capital’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-5,036	Closed	-$265K	–	164
2017 Q1	$265K	Buy	+5,036	New	+$255K	0.09%	94

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Hotchkis & Wiley Capital Management Los Angeles, California $32.4B AUM 17.21% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Cognios Capital's GSK Position: Q2 2017 in Review

Cognios Capital sold out of GSK (GSK) in Q2 2017, closing a stake of 5,036 shares — an estimated $265K sold.

Cognios Capital first reported a position in GSK in Q1 2017 and held it in 1 quarter. The position peaked at $265K in Q1 2017. 779 funds tracked by Wall St. Rank hold GSK as of Q2 2017.

Cognios Capital reported no remaining GSK position as of Q2 2017 after selling out during the quarter.
Cognios Capital sold 5,036 GSK shares in Q2 2017, an estimated $265K.
Cognios Capital first reported a position in GSK in Q1 2017 and held it in 1 quarter.
Cognios Capital's GSK position peaked at $265K in Q1 2017.
779 funds tracked by Wall St. Rank held GSK as of Q2 2017.

Based on Cognios Capital's 13F filing for Q2 2017, filed 11 Aug 2017.